TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
129 hedge funds and large institutions have $834M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 29 reducing their positions, and 14 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 29
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
9% more funds holding
Funds holding: 118 → 129 (+11)
22% less capital invested
Capital invested by funds: $1.07B → $834M (-$236M)
28% less call options, than puts
Call options by funds: $1.92M | Put options by funds: $2.67M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$27.9M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$22.5M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$71.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$13.1M |
| 5 |
Millennium Management
New York
|
-$9.18M |
TCRR Hedge Fund Activity: Q1 2021 in Review
129 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2021, worth a combined $834M — down 22% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TCRR positions and 14 closed out — a net gain of 11 holders — while 60 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $33M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $71.3M sold.
- 129 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2021, up from 118 in Q4 2020.
- Funds reported $834M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2021, down 22% quarter-over-quarter.
- 25 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +11 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2021 was State Street, an estimated $33M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2021 was Consonance Capital Management, an estimated $71.3M sold.
Based on aggregated 13F filings for Q1 2021.